Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1998-2-24
|
pubmed:abstractText |
Ten pediatric patients with solid tumors and chemotherapy-induced neutropenia were given recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM CSF). The duration of the neutropenic phase was then compared with the results obtained from eight patients also with solid tumors, but not treated with rHuGM-CSF. It was found that rHuGM-CSF treatment significantly decreased the duration of the neutropenic phase. Endogenous plasma GM-CSF, IL-3, and IL-4 levels were also measured in the study group and in healthy children. No significant correlation has been found between plasma GM-CSF concentrations and absolute neutrophil counts. However, IL-3 levels of the neutropenic patients positively correlated with platelet counts. Furthermore, IL-4 concentrations were positively correlated with the GM-CSF level in the same individual. Plasma GM-CSF, IL-3, and IL-4 levels in the neutropenic solid tumor group were found to be significantly higher than those in healthy children. Plasma IL-4 levels were significantly elevated in patients with osteosarcoma as compared to patients with other solid tumors. Although rHuGM-CSF has a half-life of only two to three hours, one day after rHuGM-CSF therapy, plasma GM-CSF levels were found to be higher than initial values. In contrast, plasma IL-4 values decreased significantly after administration of rHuGM-CSF. The probable mechanisms for the changes in cytokine levels are discussed.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0041-4301
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
473-81
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9433149-Adolescent,
pubmed-meshheading:9433149-Case-Control Studies,
pubmed-meshheading:9433149-Child,
pubmed-meshheading:9433149-Child, Preschool,
pubmed-meshheading:9433149-Female,
pubmed-meshheading:9433149-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:9433149-Humans,
pubmed-meshheading:9433149-Interleukin-3,
pubmed-meshheading:9433149-Interleukin-4,
pubmed-meshheading:9433149-Male,
pubmed-meshheading:9433149-Neoplasms,
pubmed-meshheading:9433149-Neutropenia,
pubmed-meshheading:9433149-Recombinant Proteins,
pubmed-meshheading:9433149-Regression Analysis,
pubmed-meshheading:9433149-Statistics, Nonparametric
|
pubmed:articleTitle |
Recombinant human granulocyte-macrophage colony-stimulating factor therapy and endogenous plasma GM-CSF, IL-3, IL-4 concentrations in pediatric patients with solid tumors.
|
pubmed:affiliation |
Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|